MARKET

OTIC

OTIC

Otonomy Inc
OTCPK
0.115
+0.006
+5.02%
Opening 11:52 02/08 EST
OPEN
0.110
PREV CLOSE
0.110
HIGH
0.115
LOW
0.110
VOLUME
396.98K
TURNOVER
44.60K
52 WEEK HIGH
2.590
52 WEEK LOW
0.060
MARKET CAP
6.57M
P/E (TTM)
-0.1496
1D
5D
1M
3M
1Y
5Y
Tracking Baker Brothers Portfolio - Q3 2022 Update
Seeking Alpha · 01/06 07:38
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/26/2022 13:07
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 12/23/2022 17:31
BRIEF-Otonomy Announces Change In Stock Exchange Listing
Reuters · 12/22/2022 12:56
Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket
Benzinga · 12/22/2022 11:17
Otonomy Shares to be Suspended From Nasdaq Trading
Otonomy Shares to be Suspended From Nasdaq Trading
MT Newswires · 12/22/2022 09:48
Otonomy Adopts Dissolution & Liquidation Plans, Implements Workforce Reduction
Benzinga · 12/20/2022 14:51
Otonomy Plans to File for Liquidation; Lays off All Employees; Shares Fall
Otonomy Plans to File for Liquidation; Lays off All Employees; Shares Fall
MT Newswires · 12/20/2022 14:36
More
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

Webull offers kinds of Otonomy Inc stock information, including OTCPK:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.